GSA CAPITAL PARTNERS LLP - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 29 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GSA CAPITAL PARTNERS LLP ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$398,000
+1070.6%
1,205,873
+5814.0%
0.07%
+1550.0%
Q2 2019$34,000
-56.4%
20,390
-34.6%
0.00%
-50.0%
Q1 2019$78,000
-72.0%
31,200
-43.5%
0.01%
-46.7%
Q3 2018$279,000
-57.1%
55,200
-72.3%
0.02%
-53.1%
Q2 2018$650,000199,5000.03%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 535,590$2,705,0001.58%
Millrace Asset Group, Inc. 200,000$1,010,0000.79%
Private Wealth Partners, LLC 1,000,000$5,050,0000.77%
PERKINS CAPITAL MANAGEMENT INC 249,700$1,261,0000.76%
Timpani Capital Management LLC 206,119$1,041,0000.30%
Diametric Capital, LP 64,329$325,0000.28%
Granahan Investment Management 941,170$4,753,0000.26%
Kalos Management, Inc. 69,900$308,0000.16%
SYMMETRY PEAK MANAGEMENT LLC 85,000$429,0000.15%
B. Riley Wealth Advisors, Inc. 250,000$1,263,0000.15%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders